Cytora has developed a revolutionary technology to produce “off-the-shelf” (allogeneic) therapeutic doses of hOMSC to treat some of the most challenging diseases of this decade including chronic wounds such as diabetic foot ulcers (DFU) autoimmune and degenerative diseases such as Parkinson’s Disease, Multiple System Atrophy (MSA), and Alzheimer’s Disease.
Milestones
The company has successfully completed a Phase I/IIa clinical trial for the DFU indication and has completed patient enrollment for the Phase I MSA clinical trial.
Building the next generation GMP production line
OUR NEW FACILITY
• Total of 500sqm (offices, labs and clean room).
• 60sqm cGMP manufacturing facility, including in-house cell bank storage in liquid nitrogen and warehouse.
• Cytora’s manufacturing facility is Grade B compliant and includes all the equipment for cell therapy manufacturing process.
• Cytora’s labs are equipped with Real Time PCR, ELISA, fluorescence microscope and other state-of-the-art lab equipment for R&D and QC purposes.
Vision
Cytora’s vision is to improve and save
the lives of millions of patients worldwide suffering from incurable and devastating diseases using Cytora’s unique patented neural crest stem cell platform technology.
Mission
Cytora’s mission is to establish
off-the-shelf hOMSC-based products as the standard of care for people facing challenging diseases, now and in the future.